The Week In... Pharma (24-28/02)
  • Posted on: 28/02/2020
  • Category: Industry

The Week In... Pharma (24-28/02)

Chinese biopharma company, Clover Biopharmaceuticals, to collaborate with GSK on a coronavirus vaccine candidate, it’s 20 years since the first internet pharmacy launched, an AI-created antibiotic can kill many antibiotic-resistant bacteria and Sanofi is to create the world’s second largest API company.

Interested in Star’s innovative outsourcing and resourcing solutions?

Contact Operations Director, Mark Ward, on 07872 105 540 or email mark.ward@starmedical.co.uk.

On the hunt for a new role, or just curious?

Visit our candidate page, submit your CV to candidates@starmedical.co.uk, or give our offices a ring!

Clover and GSK collaborate on coronavirus vaccine candidate

Clover Biopharmaceuticals, a China based global clinical-stage biotechnology company […], announced that it has entered into a research collaboration with GSK for its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer).

New AI-created antibiotic can kill many antibiotic-resistant bacteria

A team of researchers have discovered a “powerful” new antibiotic compound using a machine-learning algorithm, or artificial intelligence (AI).

Supporting the next generation of digital pharmacies

This year marks the 20th anniversary of the UK’s first internet pharmacy and the sector has steadily increased, particularly after the 2005 rule change that meant they could start filling NHS prescriptions.

Sanofi to create world’s second largest API company

Sanofi plans to create a new European company dedicated to the production and marketing to third parties of active pharmaceutical ingredients (API), which are the essential molecules responsible for the beneficial effects used in the composition of any drug.

Lilly’s Trulicity scores CV reduction indication in the US

Eli Lilly’s GLP-1 agonist Trulicity has won a new indication in the US, to reduce cardiovascular events in adults with and without established cardiovascular disease. 

While you’re here…

…and are interested in our content, why not sign up to our newsletter?

It’s just below here.